ArticleWorld journal of gastroenterology2022
How has the disease course of pediatric ulcerative colitis changed throughout the biologics era? A comparison with the IBSEN study.
Article in World journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The ImproveCareNow Registry: Prediction of different remission rates in pediatric ulcerative colitis.JPGN reports · 2026Article
- Toward personalized therapeutic drug monitoring of ustekinumab in Crohn's disease: influence of previous exposure to biologics.Therapeutic advances in gastroenterology · 2025Article
- Long-term prognosis and clinical practice for new-onset ulcerative colitis in the era of biologics: A Japanese retrospective study.JGH open : an open access journal of gastroenterology and hepatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Korea, infliximab was approved for use in children with ulcerative colitis (UC) in October 2012.
aimTo compare the clinical course of UC before and after the introduction of biological agents, and to compare with the IBSEN study.
methodsPatients under 18 years of age, who were diagnosed with UC and followed from January 2003 to October 2020, were included in the study. Group A (
resultsAfter 2 years of treatment, colonoscopy evaluation revealed different outcomes in the two treatment groups. Remission was confirmed in 14 patients (29.2%) of Group A, and in 31 patients (50.0%) of Group B (
conclusionThe incidence of relapse has decreased and the steroid-free period has increased after the introduction of the biological agent. The clinical course also showed a different pattern from that of IBSEN study. The active use of biological agents may change the long-term disease course in moderate to severe pediatric UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.